...
首页> 外文期刊>Journal of Drug Delivery and Therapeutics >SOLUBILITY AND DISSOLUTION ENHANCEMENT OF WATER INSOLUBLE DRUG BY USING DIFFERENT HYDROPHILLIC CARRIERS AND FORMULATED INTO TABLET DOSAGE FORM
【24h】

SOLUBILITY AND DISSOLUTION ENHANCEMENT OF WATER INSOLUBLE DRUG BY USING DIFFERENT HYDROPHILLIC CARRIERS AND FORMULATED INTO TABLET DOSAGE FORM

机译:通过使用不同的亲水性载体并将其配制为片剂的剂型来增强水不溶性药物的溶解度和溶解度

获取原文
           

摘要

Rosuvastatin calcium is a BCS class II drug (low solubility and high permeability), used as a lipid lowering agent by acting as HMG CoA reductase inhibitor and it is used for the management of hyperlipidemia. Increase in the solubility of the poorly water soluble drug is the most challenging aspect for various new chemical entities which leads to the unsatisfactory dissolution profile, consequently, the bioavailability. There are various techniques to enhance the solubility of the drug, such as particle size reduction, nanosuspension, use of surfactants, salt formation, pH modifier, solid dispersion etc. Solid dispersions in water-soluble carriers have attracted considerable interest as a means of improving the dissolution rate and hence possibly bioavailability, of a range of hydrophobic drugs. Carriers are the major players in these formulations, e.g., hydroxypropylmethylcellulose, ethyl cellulose, methyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol etc. HPMC and EC is one of the most efficient polymers among all of these to work as a carrier for these drugs to enhance solubility. Four ratios of drug: carrier were prepared (1:1, 1:3, 1:5, 1:7) and 1:7 was the optimized ratio which shows a maximum release of the drug via dissolution profile. In the present work, Solid Dispersions were prepared by Kneading technique to enhance the solubility of Rosuvastatin Calcium. Solid dispersions were evaluated for Fourier transform infrared spectroscopy (FTIR), thermal analysis, dissolution studies, powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), and stability studies to confirm enhancement in solubility. The prepared solid dispersions are formulated into tablet dosage form and characterized by various parameters i.e. weight variation, hardness, friability, disintegration, and dissolution rate. The evaluated parameters of tablet dosage form show increase in solubility and dissolution rate of the pure drug.
机译:瑞舒伐他汀钙是一种BCS II类药物(低溶解度和高渗透性),通过充当HMG CoA还原酶抑制剂而用作降脂剂,并用于治疗高脂血症。水溶性差的药物的溶解度的增加是各种新化学实体最具挑战性的方面,这导致了不令人满意的溶出曲线,因此导致了生物利用度。有多种提高药物溶解度的技术,例如减小粒径,纳米悬浮液,使用表面活性剂,成盐,pH调节剂,固体分散体等。作为改进方法,水溶性载体中的固体分散体引起了广泛的关注。一系列疏水性药物的溶出度,并因此可能具有生物利用度。载体是这些配方中的主要角色,例如羟丙基甲基纤维素,乙基纤维素,甲基纤维素,聚乙烯吡咯烷酮,聚乙烯醇等。HPMC和EC是所有这些中最有效的聚合物之一,可作为这些药物的载体来增强溶解度。制备了药物:载体的四个比率(1∶1、1∶3、1∶5、1∶7),并且1∶7是最优化的比率,其通过溶出曲线显示了药物的最大释放。在本工作中,通过捏合技术制备了固体分散体,以增强瑞舒伐他汀钙的溶解度。对固体分散体进行了傅里叶变换红外光谱(FTIR),热分析,溶解度研究,粉末X射线衍射(PXRD),扫描电子显微镜(SEM)和稳定性研究,以确认溶解度的提高。将制备的固体分散体配制成片剂剂型,并通过各种参数表征,即重量变化,硬度,易碎性,崩解和溶解速率。片剂剂型的评估参数表明纯药物的溶解度和溶解速率增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号